Viking Therapeutics shares fall 7.57% premarket after Q2 net loss widens, misses expectations.

jueves, 24 de julio de 2025, 5:34 am ET1 min de lectura
VKTX--
Viking Therapeutics, Inc. fell 7.57% in premarket trading, with the company reporting a wider net loss for Q2 2025, missing expectations. The company's shares fell after hours following the earnings report, which highlighted a widening loss and missed expectations.

Viking Therapeutics shares fall 7.57% premarket after Q2 net loss widens, misses expectations.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios